Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5,304 JPY | -0.86% | -2.14% | -21.89% |
Mar. 31 | A second Kobayashi Pharma Japan factory inspected over deaths | RE |
Mar. 30 | Kobayashi factory searched over deaths possibly linked to supplements | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Personal Products
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.89% | 2.57B | C+ | ||
+13.12% | 391B | C- | ||
+11.50% | 132B | B- | ||
+18.03% | 77.19B | A+ | ||
-12.37% | 67B | A- | ||
-11.46% | 46.43B | B+ | ||
+6.60% | 34.77B | B- | ||
+11.20% | 18.02B | A- | ||
+20.23% | 16.21B | B | ||
+0.26% | 11.86B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4967 Stock
- Ratings Kobayashi Pharmaceutical Co., Ltd.